This market resolves to Yes if NICE publicly issues a recommendation for the use of GLP-1 receptor agonists as a treatment option for eating disorders (e.g., binge eating disorder, anorexia, bulimia) by August 31, 2026. This includes any instruction or guidance that GLP-1 receptor agonists be considered as part of the treatment for such conditions. If no such recommendation is made by NICE by this date, the market resolves to No.
Other open markets in Health
This market resolves to Yes if any new state-level regulations specific to Utah's AI-driven prescription refill pilot program are officially enacted by August 31, 2026. This includes legislation, healthcare board policies, or executive actions aimed explicitly at modifying, expanding, or restricting the program. Public announcements or documented evidence of such changes will determine resolution.
This market resolves to Yes if the UK government, or the National Institute for Health and Care Excellence (NICE), officially announces updated guidance explicitly concerning the management of polycystic ovary syndrome (PCOS) by August 31, 2026. If no such announcement is made by that date, the market resolves to No. This market was prompted by *The Pharmaceutical Journal* reporting on the establishment of the first UK guidance for polyendocrine metabolic ovarian syndrome.
This market resolves to Yes if the CDC reports, by August 31, 2026, that the U.S. death rate for 2026 remains at a record low as described in its provisional data release for the year. This will be based on official CDC death statistics or provisional updates publicly released by that date.
This market resolves to Yes if the Centers for Disease Control and Prevention (CDC) makes an official recommendation, announcement, or guideline by August 31, 2026, advocating for the reclassification of Grade Group 1 prostate cancer (the earliest and lowest-risk form of the disease) as a precancerous condition. Any such confirmation must be made publicly on the CDC's website, press releases, or official communications. If no such announcement is made by August 31, 2026, this market resolves to No.
This market resolves to Yes if Medicare officially announces its policy regarding the coverage of GLP-1 drugs for weight loss by August 15, 2026. The resolution will be based on official statements or announcements from Medicare or the Centers for Medicare & Medicaid Services (CMS).
This market resolves to Yes if Medicare officially announces coverage for the breast cancer test Oncotype DX by August 31, 2026. Oncotype DX is a trusted diagnostic test used by cancer specialists to guide treatment decisions. The market will resolve based on an official announcement from Medicare or related federal agencies confirming the coverage policy by the specified date.